Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Results Imminent From Sweden’s Pilot Of Novel Antibiotic Reimbursement Model

Executive Summary

If successful, a new Swedish model for reimbursing antibiotics that involves guaranteed minimum annual revenues for companies, could be tested on other kinds of products.

You may also be interested in...



England: Shionogi And Pfizer Ink ‘World First’ Payment Model Deal For Antibiotics

Shionogi and Pfizer have formally agreed to a scheme that offers companies a new and sustainable payment model for innovating in antibiotics.

Roche Wants EU Pharma Legislative Revision To ‘Dare Something New’

New, more flexible regulatory approaches will be needed to deal with the integrated therapies coming through company pipelines, and the European Medicines Agency should play a “key orchestrating role” in smoothing the way, says Sabine Atzor, Roche’s head of EU regulatory policies.

WHO’s Draft Pandemic Treaty Calls For More Regulatory Harmonization

Regulatory convergence and the sharing of dossiers, together with the timely and equitable sharing of pathogens, could help to speed up access to diagnostics, vaccines and medications in pandemic situations, according to the first draft of the World Health Organization’s proposed pandemic treaty.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS147360

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel